RESUMO
BACKGROUND: Abnormal effort-based decision-making represents a potential mechanism underlying motivational deficits (amotivation) in psychotic disorders. Previous research identified effort allocation impairment in chronic schizophrenia and focused mostly on physical effort modality. No study has investigated cognitive effort allocation in first-episode psychosis (FEP). METHOD: Cognitive effort allocation was examined in 40 FEP patients and 44 demographically-matched healthy controls, using Cognitive Effort-Discounting (COGED) paradigm which quantified participants' willingness to expend cognitive effort in terms of explicit, continuous discounting of monetary rewards based on parametrically-varied cognitive demands (levels N of N-back task). Relationship between reward-discounting and amotivation was investigated. Group differences in reward-magnitude and effort-cost sensitivity, and differential associations of these sensitivity indices with amotivation were explored. RESULTS: Patients displayed significantly greater reward-discounting than controls. In particular, such discounting was most pronounced in patients with high levels of amotivation even when N-back performance and reward base amount were taken into consideration. Moreover, patients exhibited reduced reward-benefit sensitivity and effort-cost sensitivity relative to controls, and that decreased sensitivity to reward-benefit but not effort-cost was correlated with diminished motivation. Reward-discounting and sensitivity indices were generally unrelated to other symptom dimensions, antipsychotic dose and cognitive deficits. CONCLUSION: This study provides the first evidence of cognitive effort-based decision-making impairment in FEP, and indicates that decreased effort expenditure is associated with amotivation. Our findings further suggest that abnormal effort allocation and amotivation might primarily be related to blunted reward valuation. Prospective research is required to clarify the utility of effort-based measures in predicting amotivation and functional outcome in FEP.
Assuntos
Cognição/fisiologia , Motivação/fisiologia , Desempenho Psicomotor/fisiologia , Transtornos Psicóticos/psicologia , Adolescente , Adulto , Antipsicóticos/farmacologia , Estudos de Casos e Controles , Cognição/efeitos dos fármacos , Feminino , Humanos , Masculino , Motivação/efeitos dos fármacos , Desempenho Psicomotor/efeitos dos fármacos , Transtornos Psicóticos/tratamento farmacológico , Tempo de Reação/efeitos dos fármacos , Tempo de Reação/fisiologia , Análise de Regressão , Recompensa , Adulto JovemRESUMO
Androgen deficiency in the ageing male (ADAM) was proposed to characterize a symptom cluster of decrease in sexual function and strength, dysphoria and osteopenia in ageing men with decreased levels of androgens. Unlike menopause, literature on the topic is scarce and focuses mainly on the physiological aspects of the problem. However, men with ADAM also face a milieu of psychosocial stressors which may adversely affect their mental health. It is pertinent to examine ADAM within a psychological context. This study aims to determine the prevalence of symptoms of ADAM among Chinese men, and to examine their relationship with psychological distress and quality of life. A cross-sectional design was employed with standardized questionnaires to assess symptoms of ADAM and related psychological factors. The ADAM questionnaire, Hospital Anxiety and Depression Scale, Perceived Stress Scale, General Health Questionnaire and Short Form Health Survey-12 were administered to a community sample of 311 Chinese men (aged 40-80) attending a family medicine clinic in Hong Kong. Demographic information was also collected. A total of 87.8% of the sample was screened ADAM positive using the ADAM questionnaire. Age, duration of marriage, occupation, household income and physical health were found to be significantly associated with ADAM status. ADAM positive individuals were found to have higher anxiety and depression scores, higher stress level, higher psychiatric morbidity and poorer physical and mental quality of life compared with their ADAM negative counterparts. Symptoms of ADAM are prevalent among the Chinese. ADAM positivity as measured by the ADAM questionnaire is associated with poorer psychological well-being and quality of life in the ageing population. Further research and clinical attention to the psychological needs of this population is warranted.
Assuntos
Envelhecimento/psicologia , Androgênios/deficiência , Povo Asiático/psicologia , Qualidade de Vida , Adulto , Idoso , Idoso de 80 Anos ou mais , Ansiedade/epidemiologia , Ansiedade/psicologia , Transtorno Depressivo/epidemiologia , Transtorno Depressivo/psicologia , Inquéritos Epidemiológicos , Hong Kong/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Fatores de RiscoRESUMO
Hashimoto's encephalopathy may present with a variety of neurological symptoms and signs, including myoclonus, epileptic seizures, disturbance of consciousness, psychosis, ataxia, and presenile dementia. This report is of a 57-year-old woman with a history of thyroid disease who was investigated for generalised seizures, rapid decline in cognitive function, increasing dependency, and gradual change in personality. High thyroid autoantibody titres confirmed the diagnosis of Hashimoto's encephalopathy and her symptoms improved with treatment with prednisolone. The differential diagnosis of presenile dementia, aetiology and pathogenesis of Hashimoto's encephalomyelitis, and treatment options are discussed. Hashimoto's encephalomyelitis should be considered in the differential diagnosis of presenile dementia, particularly in patients with a history of thyroid disease.
Assuntos
Doença de Alzheimer/etiologia , Doença de Alzheimer/diagnóstico , Encéfalo/diagnóstico por imagem , Encéfalo/patologia , Encefalopatias/complicações , Encefalopatias/diagnóstico , Encefalopatias/tratamento farmacológico , Diagnóstico Diferencial , Encefalite , Feminino , Glucocorticoides/uso terapêutico , Doença de Hashimoto/complicações , Doença de Hashimoto/diagnóstico , Doença de Hashimoto/tratamento farmacológico , Humanos , Imageamento por Ressonância Magnética , Pessoa de Meia-Idade , Prednisolona/uso terapêutico , Doenças da Glândula Tireoide/complicações , Tomografia Computadorizada por Raios XRESUMO
Two women presented independently with a clinical picture of mania-like psychosis after taking over-the-counter herbal slimming pills. Subsequent toxicology investigation found sibutramine in the samples of both patients. Sibutramine is an effective pharmacological treatment for obesity with a relatively favourable side-effect profile. However, neuropsychiatric side-effects of sibutramine have emerged with increasing use of the medication. Sibutramine may be associated with the development of psychotic symptoms in susceptible individuals. Further studies should aim at establishing any causal relationship between sibutramine and psychosis. There also seems to be an emerging trend of adulteration of over-the-counter slimming products with pharmaceutical analogues in Hong Kong. Physicians should be vigilant to the possibility of non-prescribed drug use when patients present with suspicious symptoms while using herbal remedies.